11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 3, 2005, Pages 289-303

  Fotsch, Christopher ^a   Askew, Ben C ^a   Chen, Jian Jeffrey ^a  

^a AMGEN INC   (United States)

Author keywords

11 Hydroxysteroid dehydrogenase 1 (11 HSD1); Diabetes; Gluconeogenesis; Hydroxysteroid dehydrogenase; Inhibitor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; ACETAMIDE DERIVATIVE; ADAMANTYL ACETAMIDE DERIVATIVE; AMINOTHIAZOLE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; CARBENOXOLONE; CARBOXYLIC ACID DERIVATIVE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR STIMULATING AGENT; GLUCOSE; GLYCYRRHETINIC ACID DERIVATIVE; GLYCYRRHIZA EXTRACT; HETEROARENESULFONAMIDE; HORMONE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; INSULIN; LACTAM DERIVATIVE; MONOCLONAL ANTIBODY; N THIADIAZOLYL ARENESULFONAMIDE; N THIENYL ARENESULFONAMIDE; OXIDOREDUCTASE INHIBITOR; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; STREPTOZOCIN; SULFONAMIDE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRITIS; CANCER; DEMENTIA; DEPRESSION; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; GLAUCOMA; GLUCONEOGENESIS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IC 50; INFLAMMATORY DISEASE; INSULIN SENSITIVITY; MALARIA; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOPOROSIS; PATENT; PATHOPHYSIOLOGY; PEPTIC ULCER; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SYNDROME X; TUBERCULOSIS; VIRUS INFECTION;

EID: 15544380476     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.3.289     Document Type: Review

References (31)

1. ZIMMET PZ, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. Nature (2001) 414 782-787.
2. ROSS SA, GULVE EA, WANG M: Chemistry and biochemistry of Type 2 diabetes. Chem. Rev. (2004) 104(3):1255-1282.
3. WAJCHENBERG BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Rev. (2000) 21(6):697-738.
4. SKYLER JS: Diabetes mellitus: pathogenesis and treatment strategies. J. Med. Chem. (2004) 47(17):4113-4117.
5. RASK E, OLSSON T, SODERBERG S et al.: Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. (2001) 86(3):1418-1421.
6. DEFRONZO RA: Pathogenesis of Type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. (1997) 5:177-269.
7. NOBEL S, ABRAHMSEN L, OPPERMANN U: Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Euro. J. Biochem. (2001) 268(15):4113-4125.
8. FRIEDMAN JE, YUN JS, PATEL YM, MCGRANE MM, HANSON RW: Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J. Biol. Chem. (1993) 268(17):12952-12957.
9. HANSON RW, RESHEF L: Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Ann. Rev. Biochem. (1997) 66:581-611.
10. SECKL JR, WALKER BR: Minireview: 11β-hydroxysteroid dehydrogenase Type 1 - a tissue-specific amplifier of glucocorticoid action. Endocrinology (2001) 142(4):1371-1376.
11. STULNIG TM, WALDHÄUSL W: 11β-hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes. Diabetologia (2004) 47 1):1-11.
12. KOTELEVTSEV Y, HOLMES MC, BURCHELL A et al. 11β-hydroxysteroid dehydrogenase Type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA (1997) 94(26):14924-14929.
13. MASUZAKI H, PATERSON J, SHINYAMA H et al.: A transgenic model of visceral obesity and the metabolic syndrome. Science (2001) 294(5549):2166-2170.
14. WALKER BR, SECKL JR: 11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Ther. Targets (2003) 7(6):771-783.
15. PAVLOVA SI, UTESHEV BS, SERGEEV AV: Licorice root: possible mechanisms of antioxidant, anti-carcinogen, and anti-tumor properties. Pharma. Chem. J. (2003) 37(6):314-317.
16. HATTORI M, SAKAMOTO T, KOBASHI K, NAMBA T: Metabolism of glycyrrhizin by human intestinal flora. Planta medica (1983) 48 1):38-42.
17. HATTORI M, SAKAMOTO T, YAMAGISHI T et al.: Metabolism of glycyrrhizin by human intestinal flora. II. Isolation and characterization of human intestinal bacteria capable of metabolizing glycyrthizin and related compounds. Chem. Pharm. Bull. (1985) 33 1):210-217.
18. HULT M, JORNVALL H, OPPERMANN UC: Selective inhibition of human Type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Letts. (1998) 441(1):25-28.
19. WALKER BR, CONNACHER AA, LINDSAY RM, WEBB DJ, EDWARDS CRW: Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrin. Metab. (1995) 80 11):3155-3159.
20. ANDREWS RC, ROOYACKERS O, WALKER BR: Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with Type 2 diabetes. J. Clin. Endocrin. Metab. (2003) 88(1):285-291.
21. BARF T, VALLGRDA J, EMOND R et al.: Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase Type 1. J. Med. Chem. (2002) 45(18):3813-3815.
22. ALBISTON AL, OBEYESEKERE VR, SMITH RE, KROZOWSKI ZS: Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase Type 2 enzyme. Mol. Cell. Endocrinol. (1994) 105(2):R11-R17.
23. +-dependent isoform of 11β-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J. Biol. Chem. (1994) 269(42):25959-25962.
24. KOTELEVTSEV Y, BROWN RW, FLEMING S et al.: Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase Type 2. J. Clin. Invest. (1999) 103(5):683-689.
25. CHROUSOS GP: Is 11β-hydroxysteroid dehydrogenase Type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc. Natl. Acad. Sci. USA (2004) 101(17):6329-6330.
26. OLSON S, BALKOVEC J, GAO Y-D et al.: Selective inhibitors of 11β-hydroxysteroid dehydrogenase Type 1. adamantyl triazoles as pharmacological agents for the treatment of metabolic syndrome. Keystone Symposia: Molecular Controls of Adipogenesis and Obesity. Alberta, Canada (2004) 329.
27. HERMANOWSKI-VOSATKA A, MUNDT S, NUNES C et al.: 11βHSD1 inhibition ameliorates metabolic syndrome in mice. Kystone Symposia: Molecular Controls of Adipogenesis and Obesity. Alberta, Canada (2004) 215.
28. KURZ G, BARF T, VALLGARDA J et al.: For mice and men? Inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 with anti-diabetic potential. Drugs Fut. (2004) 29(Suppl. A):101.
29. RAUZ S, CHEUNG CM: WOOD PJ et al.: Inhibition of 11β-hydroxysteroid dehydrogenase Type 1 lowers intraocular pressure in patients with ocular hypertension. Q. J. Med. (2003) 96 481-90.
30. HOSFIELD, D, YIQIN W et al.: Conformational flexibility in crystal structures of human 11β-HSD1 provide insights into glucocorticoid, interconversion and enzyme regulation. J. Biol. Chem. in press.
31. OGG D, BJÖRN E et al. The crystal structure of guinea pig 11βHSD1 provides a model for enzyme-lipid interactions. J. Biol. Chem. in press.